Filtered By:
Cancer: HER2

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 260 results found since Jan 2013.

The Role, Function, and Mechanism of Long Intergenic Noncoding RNA1184 (linc01184) in Colorectal Cancer.
Conclusions: The findings reveal for the first time that linc01184 is an enhancer for the proliferation and invasion of CRC by functioning as a ceRNA through the linc01184-miR-331-HER2-p-Akt/ERK1/2 pathway regulatory network. PMID: 33564344 [PubMed - in process]
Source: Disease Markers - February 12, 2021 Category: Laboratory Medicine Tags: Dis Markers Source Type: research

LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3.
Abstract Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with fewer treatment options than other types of invasive breast cancer due to the loss of the estrogen, progesterone receptors and low levels of the HER2 protein, resulting in a poor prognosis for these patients. Here, we found that the expression of the lncRNA, ZFAS1, was significantly downregulated (∼3.0-fold) in blood samples of TNBC patients (n = 40) compared to matched healthy controls (n = 40). Functionally, silencing of ZFAS1 promoted cell proliferation and colonization of human MDA-MB-231 TNBC cells by ...
Source: Biochimie - January 8, 2021 Category: Biochemistry Authors: Sharma U, Barwal TS, Khandelwal A, Malhotra A, Rana MK, Singh Rana AP, Imyanitov EN, Vasquez KM, Jain A Tags: Biochimie Source Type: research

Cancers, Vol. 13, Pages 80: The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
Conclusion: High expression of LAIR-1 is associated with poor clinical outcome in BC. Association with immune cells and immune checkpoint markers warrant further studies to assess the underlying mechanistic roles.
Source: Cancers - December 30, 2020 Category: Cancer & Oncology Authors: Chitra Joseph Mansour A. Alsaleem Michael S. Toss Yousif A. Kariri Maryam Althobiti Sami Alsaeed Abrar I. Aljohani Pavan L. Narasimha Nigel P. Mongan Andrew R. Green Emad A. Rakha Tags: Article Source Type: research

High expression of ZNF652 promotes carcinogenesis and progression of breast cancer.
CONCLUSIONS: ZNF652 is highly expressed in breast cancer tissues and cells to promote the development and progression of breast cancer and may serve as a potential molecular target for diagnosis and treatment of the malignancy. PMID: 33380394 [PubMed - in process]
Source: Journal of Southern Medical University - December 30, 2020 Category: Universities & Medical Training Authors: Lei T, Xiao B, He Y, Sun Z, Li L Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: research

GSE152317 Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer
Contributors : Jeremy M Simon ; Qing ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTriple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG –dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX1) as an essential gene for TNBC tumorigenesis. BBOX1 depletion inhibits TNBC cell growth while not affecting normal breast cells. Mechanistically, BBOX1 binds with the calcium ch...
Source: GEO: Gene Expression Omnibus - December 2, 2020 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE160001 FOXA1-dependent responses of the HER2+ SKBR-3 cell line to lapatinib
Contributors : Gary L Johnson ; Steven P AngusSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSKBR-3 HER2+ breast cancer cells were treated with 25 nM Dharmacon siGENOME non-targeting (NT) siRNA control pool or siRNA pool targeting FOXA1 for 48h, then treated with either DMSO or 300nM lapatinib for 24h.
Source: GEO: Gene Expression Omnibus - October 26, 2020 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Calcium based siRNA coating: a novel approach for knockdown of HER2 gene in MCF-7 cells using gold nanoparticles.
Authors: Sami A, Naqvi SMS, Qayyum M, Raza Rao A, Sabitaliyevich UY, Ahmad MS Abstract Surface functionalization of nanoparticles (NPs) for therapeutic siRNA delivery into cancer cells has gained interest. The present study was designed for surface functionalization of gold nanoparticles (AuNPs) for efficient siRNA delivery and knockdown in cancer cells. In order to achieve this objective, AuNPs were coated with HER2-siRNA in the presence of 11-mercaptoundecanoic acid (11-MUA), calcium chloride (CaCl2) and polyethyleneimine (PEI) in alternate charge bearing successive layers. MCF-7 cells were cultured and transfect...
Source: Cellular and Molecular Biology - October 14, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
This study aimed to investigate the antiproliferative property of cucurbitacin B on KKU-100 CCA cells. The determination of underlying molecular mechanisms was also carried out. The results revealed that cucurbitacin B suppressed growth and replicative ability to form colonies of CCA cells, suggesting the antiproliferative effect of this compound against the cells. Flow cytometry analysis demonstrated that the interfering effect of cucurbitacin B on the CCA cell cycle at the G2/M phase was accountable for its antiproliferation property. Accompanied with cell cycle disruption, cucurbitacin B altered the expression of protei...
Source: The American Journal of Chinese Medicine - September 8, 2020 Category: Complementary Medicine Authors: Klungsaeng S, Kukongviriyapan V, Prawan A, Kongpetch S, Senggunprai L Tags: Am J Chin Med Source Type: research

Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer Molecular Bases of Disease
In this study, we discovered that combined p53- and PTEN-deficiency in TNBC activates expression of the transcription factor mesenchyme homeobox 1 (MEOX1). We found that MEOX1 is expressed only in TNBC cells with frequent deficiencies in p53 and PTEN, and that its expression is undetectable in luminal A, luminal B, and HER2+ subtypes, as well as in normal breast cells with wild-type (WT) p53 and PTEN. Notably, siRNA knockdown of both p53 and PTEN activated MEOX1 expression in breast cancer cells, whereas individual knockdowns of either p53 or PTEN had only minimal effects on MEOX1 expression. MEOX1 knockdown abolished cell...
Source: Journal of Biological Chemistry - August 20, 2020 Category: Chemistry Authors: Mari Gasparyan, Miao-Chia Lo, Hui Jiang, Chang-Ching Lin, Duxin Sun Tags: Molecular Bases of Disease Source Type: research

ASAP Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.0c07353
Source: ACS Applied Materials and Interfaces - July 10, 2020 Category: Materials Science Authors: Long Zhang †§‡, Chaofeng Mu?‡, Tinghong Zhang†§, Yingying Wang†§, Yili Wang†§, Luhui Fan?, Cong Liu?, Hao Chen†§, Jianliang Shen*†§, Kun Wei*†§, and Huaqiong Li*†§ Source Type: research

Characterization of T ‐DM1‐resistant breast cancer cells
AbstractThe development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T ‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab and the microtubule cytotoxic agent DM1 (emtansine). Despite clinical successes achieved by targeted therapies, a large number of patients develop resistance during treatment. To explore mechanisms of resistance to T‐DM1, the MDA‐MB‐361 HER2‐positive breast cancer cell line was exposed in vitro to T‐DM1 ...
Source: Pharmacology Research and Perspectives - June 23, 2020 Category: Drugs & Pharmacology Authors: Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars ‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet Tags: ORIGINAL ARTICLE Source Type: research

GSE126894 A TFAP2C Gene Signature is Predictive of Outcome in HER2 Breast Cancer (RNA-Seq)
Conclusions: Knockdown of TFAP2C with co-knockdown of CDH5 in SKBR-3 confirmed no significant effect on invasion, though there was a slight reduction in invasiveness with knockdown of CDH5 that failed to reach statistical significance (p=0.12). These findings support the conclusion that regulation of CDH5 and CDKN1A contribute to alterations of proliferation and invasiveness induced by knockdown of TFAP2C.
Source: GEO: Gene Expression Omnibus - April 13, 2020 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers.
Authors: Okita K, Okazaki S, Uejima S, Yamada E, Kaminaka H, Kondo M, Ueda S, Tokiwa R, Iwata N, Yamasaki A, Hayashi N, Ogura D, Hirotani K, Yoshioka T, Inoue M, Masuko K, Masuko T Abstract Resistance of progressive cancers against chemotherapy is a serious clinical problem. In this context, human epidermal growth factor receptor 3 (HER3) can play important roles in drug resistance to HER1- and HER2- targeted therapies. Since clinical testing of anti-HER3 monoclonal antibodies (mAbs) such as patritumab could not show remarkable effect compared with existing drugs, we generated novel mAbs against anti-HER3. Novel ra...
Source: Oncotarget - February 1, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells
In this study, we prepared a magnetic hybrid nanostructure composed of iron oxide nanoparticles coated with caffeic acid and stabilized by layers of calcium phosphate and PEG-polyanion block copolymer for incorporation of siRNA. Transmission electron microscopy images showed monodisperse, neutrally charged compact spheres sized <100 nm. Dynamic light scattering and nanoparticle tracking analysis revealed that the nanostructure had an average hydrodynamic diameter of 130 nm. Nanoparticle suspensions remained stable over 42 days of storage at 4 and 25 °C. Unloaded caffeic acid–magnetic calcium phosphate (Caf-MCaP)...
Source: Materials Science and Engineering: C - December 26, 2019 Category: Materials Science Source Type: research